Myelodysplastic Syndromes — Written Clinical Reasoning · Phys Written Answers

Prompt

DCE-style written reasoning for Myelodysplastic Syndromes.

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

Model Answer

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

SAQ 2 — Exam trap defence (8 marks)

Prompt: Name two high-yield traps in Myelodysplastic Syndromes and how you avoid them. [1] [2]

Model Answer

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

References

[1]Nabergoj M, Bou Mjahed R, Basset V, Tsilimidos G, et al. Monocytose réactionnelle versus clonale : la leucémie myélomonocytaire chronique Rev Med Suisse, 2026.PMID 42464748
[2]Liapis K, Papadopoulos V, Stamatiou I, Koparanis D, et al. Excess risk for cardiovascular and noncardiovascular comorbidities and multimorbidity among patients with myelodysplastic syndrome: A systematic review and meta-analysis Cancer, 2026.PMID 42464613
[3]An W, Guo S, Wang H, Lv T, et al. The role and therapeutic potential of nanotechnology-mediated ferroptosis regulation in myelodysplastic syndromes Front Oncol, 2026.PMID 42459301
[4]Abdulgayoom M, Gulied A, Alshurafa A, Mohamed SF, et al. Venetoclax-Integrated Conditioning Strategies Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Myeloid Neoplasms: A Scoping Review of Emerging Evidence Eur J Haematol, 2026.PMID 41917774
[5]Carraway HE, DeAngelo DJ, Wang ES, Komrokji RS, et al. Clinical strategies for leukemia management: Recommendations from the Bridging the Gaps in Hematology Oncology Consensus Conference 2025 Leuk Res, 2026.PMID 41895012
[6]Zhang L, Ying S, Fang F, Li Q, et al. Prognostic impact of myelodysplasia-related gene mutations in ELN-2022 favorable-risk acute myeloid leukemia subtypes Ann Med, 2026.PMID 41797681
[7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

Model Answer

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

SAQ 2 — Exam trap defence (8 marks)

Prompt: Name two high-yield traps in Myelodysplastic Syndromes and how you avoid them. [1] [2]

Model Answer

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

References

[1]Nabergoj M, Bou Mjahed R, Basset V, Tsilimidos G, et al. Monocytose réactionnelle versus clonale : la leucémie myélomonocytaire chronique Rev Med Suisse, 2026.PMID 42464748
[2]Liapis K, Papadopoulos V, Stamatiou I, Koparanis D, et al. Excess risk for cardiovascular and noncardiovascular comorbidities and multimorbidity among patients with myelodysplastic syndrome: A systematic review and meta-analysis Cancer, 2026.PMID 42464613
[3]An W, Guo S, Wang H, Lv T, et al. The role and therapeutic potential of nanotechnology-mediated ferroptosis regulation in myelodysplastic syndromes Front Oncol, 2026.PMID 42459301
[4]Abdulgayoom M, Gulied A, Alshurafa A, Mohamed SF, et al. Venetoclax-Integrated Conditioning Strategies Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Myeloid Neoplasms: A Scoping Review of Emerging Evidence Eur J Haematol, 2026.PMID 41917774
[5]Carraway HE, DeAngelo DJ, Wang ES, Komrokji RS, et al. Clinical strategies for leukemia management: Recommendations from the Bridging the Gaps in Hematology Oncology Consensus Conference 2025 Leuk Res, 2026.PMID 41895012
[6]Zhang L, Ying S, Fang F, Li Q, et al. Prognostic impact of myelodysplasia-related gene mutations in ELN-2022 favorable-risk acute myeloid leukemia subtypes Ann Med, 2026.PMID 41797681
[7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922